What regulatory approvals does Thymosin Alpha-1 have?

Thymosin Alpha-1 (Zadaxin) is approved as a pharmaceutical product in more than 30 countries for the treatment of chronic hepatitis B, chronic hepatitis C (as an adjunct to interferon therapy), and as an immunological adjuvant in certain cancer contexts. It is one of the very few research peptides with broad international regulatory approval and extensive published clinical trial data. It is not FDA-approved in the United States.

How does Thymosin Alpha-1 modulate T-cell function?

Thymosin Alpha-1 acts primarily on dendritic cells and macrophages through TLR2 and TLR9 activation, inducing these antigen-presenting cells to produce IL-12 and upregulate co-stimulatory molecules (CD80, CD86). The resulting antigen-presenting cell activation then promotes cytotoxic CD8+ T-cell differentiation and activity. In immunosuppressed contexts, it also helps restore naive T-cell maturation, which declines when thymic function is impaired by aging or disease.

Is Thymosin Alpha-1 studied in the context of immune aging?

Yes. Thymic involution and declining T-cell output with aging are well-characterized features of immune senescence. Thymosin Alpha-1 has been studied in aged animal models for its ability to restore aspects of immune competence, including T-cell maturation capacity and NK cell activity. The Khavinson group and other researchers have also examined it in conjunction with aging-related immune parameters in human observational work.

What distinguishes Thymosin Alpha-1 from Thymosin Beta-4 (TB-500)?

Thymosin Alpha-1 and Thymosin Beta-4 are completely distinct peptides with unrelated mechanisms. Thymosin Alpha-1 is a 28-amino acid immunomodulatory peptide acting through TLR and dendritic cell pathways to regulate immune function. Thymosin Beta-4 (from which TB-500 is derived) is a 43-amino acid peptide acting through G-actin sequestration to regulate cellular migration and wound healing. They were both discovered in thymosin research programs but share no mechanistic or structural relationship.

Compound Reference

Thymosin Alpha-1

A thymic immunomodulatory peptide studied for TLR activation, T-cell regulation, and innate immune signaling in viral and oncology research models.

Thymic peptideC₁₂₉H₂₁₅N₃₃O₅₅Approx. 2 hours (subcutaneous, clinical data)

Innate Immune SignalingT-cell RegulationAntiviral ResearchDendritic Cell MaturationImmune Senescence

Overview

Thymosin Alpha-1 is a 28-amino acid peptide first isolated by Allan Goldstein and colleagues from thymosin fraction 5 of calf thymus tissue in the 1970s. It is now produced synthetically and is approved as a pharmaceutical product (Zadaxin) in multiple countries for treatment of chronic hepatitis B and C, and as an immunotherapy adjunct in cancer research contexts. It acts by activating Toll-like receptors (TLR2 and TLR9) on dendritic cells and macrophages, promoting innate immune recognition and antigen-presenting cell maturation, with downstream effects on cytotoxic T-cell and regulatory T-cell differentiation. Among peptide research compounds, it has one of the most extensive human clinical data profiles.

Quick Reference

Sequence: 28 amino acids, N-terminally acetylated
Origin: Isolated from thymosin fraction 5 by Allan Goldstein, 1970s
Regulatory approval: Approved as Zadaxin in 30+ countries for hepatitis B/C
Primary mechanism: TLR2/TLR9 activation, dendritic cell maturation, T-cell modulation
Purity standard: >=98% by HPLC

Mechanism

How It Works

Thymosin Alpha-1 activates TLR2 and TLR9 on dendritic cells and macrophages, triggering innate immune signaling cascades that promote dendritic cell maturation, IL-12 production, and antigen presentation capacity. Downstream effects include enhanced cytotoxic T-cell (CD8+) differentiation and activity, and modulation of regulatory T-cell (Treg) populations, supporting both immune activation in hypo-immune states and immune balance in dysregulated contexts.

Research Highlights

Key findings from the published preclinical literature.

Hepatitis B and C Clinical Trials

Multiple randomized controlled trials have examined Thymosin Alpha-1 in chronic hepatitis B and C, documenting improvements in viral clearance and sustained virological response rates, supporting its approval as Zadaxin in over 30 countries.

Cancer Immunotherapy Adjunct Research

Studies have examined Thymosin Alpha-1 as an immunotherapy adjunct in lung cancer, melanoma, and hepatocellular carcinoma models, with documented improvements in immune response parameters and some survival data in combination trials.

Sepsis and Immune Dysfunction Models

Research in sepsis-associated immune dysfunction has documented Thymosin Alpha-1 effects on monocyte and T-cell function restoration in immunoparalysis states, with clinical trials examining its role in sepsis immune reconstitution.

Dendritic Cell Maturation Assays

In vitro dendritic cell maturation studies have documented Thymosin Alpha-1 induction of CD80, CD86, MHC-II, and IL-12 expression in human monocyte-derived dendritic cells, providing mechanistic support for its antigen presentation-enhancing properties.

Research Connections

Related research areas, stacks, and comparisons involving this compound.

Frequently Asked Questions

Source This Compound

Thymosin Alpha-1 is available from Spartan Peptides at a minimum 98% HPLC-verified purity with batch-specific certificate of analysis. Domestic US supply, same-day dispatch before 2 PM EST. For in-vitro research use only.

View Thymosin Alpha-1 Product Sourcing Guide

All compounds are strictly for in-vitro research use only and not intended for human consumption.

GLP-3(Reta) | Triple-Agonist Metabolic Research

NAD+ 750mg | Cellular Energy & DNA Repair Research

MOTS-c | Mitochondrial Metabolism Research Peptide

BPC-157 5mg | Tissue Repair & Gut Health Research